Background: Pulmonary complications can cause considerable morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HCT). Other than lung transplantation (LT), no specific therapies exist for end-stage lung disease resulting from HCT-related complications such as bronchiolitis obliterans syndrome. Here we describe the indications and outcomes in patients who had LT after HCT for hematologic disease. Methods: Retrospective chart review of cases identified by the Long-Term Follow Up (LTFU) database at the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance. This database captures information provided by patients, primary physicians and by LTFU clinical service via telemedicine or by medical evaluation on site. Any patient who received a HCT at our institution with a reported history of LT was included. Results: We identified 9 recipients of allogeneic HCT between 1971 and 2006 who subsequently received LT between 1990 and 2010. The median age at the time of HCT was 16 (range, 10-35) years, and the median age at the time of LT was 34 (range, 17-44) years. The diagnosis at the time of HCT was acute leukemia (n¼7), chronic myeloid leukemia (n¼1) and aplastic anemia (n¼1). The median interval
between HCT and LT was 123 (range, 35-326) months. None of the patients had evidence of the original hematologic disorder at time of LT. Indications for LT included pulmonary fibrosis related to any history of radiation or chemotherapy before or as part of the conditioning regimen for HCT (n¼4), interstitial pneumonitis related to graft-versus-host-disease (n¼1), bronchiolitis obliterans syndrome (n¼3), and primary pulmonary hypertension (n¼1). All patients received unilateral (n¼4) or bilateral cadaveric LT (n¼5). Survival at one and five years after LT was 89% and 37%, respectively. Eight of the 9 patients died at a median of 49 months (range, 2 weeks to 87 months), and 1 is alive more than two years after LT. Deaths were attributed to chronic graft rejection and/or pulmonary infectious complications in 6 patients and anoxic brain injury from cardiac and pulmonary arrest in 1 patient. Information about the cause of death for 1 patient who died 2 weeks after LT was unavailable. According to a nationwide registry of organ transplantation (2010 OPTN/ STRT Annual Data Report), survival of all LT recipients at one year improved from 72% in 1990 to 85% in 2008; survival at five years improved from 39% in 1990 to 56% in 2004. Conclusions: LT can prolong survival in some adult and adolescent patients who suffer from end-stage pulmonary complications after HCT. These results can help to inform HCT patients who are considering LT. HCT patients with progressive pulmonary disease, but otherwise in good health, should be referred to an established LT center for evaluation, since early identification of good candidates for LT may result in better survival outcomes. HSCT is a clinical procedure that involves lethal risk. However, it sometimes arises as the only possibility for survival. Patients find a multiplicity of side effects resulting from the illness and its treatment. Graft versus host disease (GVHD) is one of the most important causes of morbidity after HSCT. We designed this study in order to evaluate the impact of graft versus host disease on QoL healtth, sexuality and fatigue in long term survivors after HSCT. This is a prospective seccional study of 214 long term survivors after HSCT, which were divided in two groups for comparison: Group 1 (G1¼89) survivors with GVHD e Group 2 (G2¼125) without GVHD. G1 was further divided into three groups according to GVHD classification: Group a (Ga) e acute GVHD; Group c (Gc) e chronic GVHD; Grupo ac (Gac) acute and chronic GVHD. Level of satisfaction about QoL, sexuality, health and fatigue were evaluated. All patients had at least 18 years old. Scales used were: WHOQOL, Functional Assessment of Cancer Therapy: Fatigue FACT-F, Karnofsky Performance Status Scale and Socioeconomic demographic survey. Level of significance in all scales was 95% (p 0.05) for all risk factors for QoL.
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Among survivors from groups G1 and G2, there were more males (61.8% and 67%), married (63% 54.8%), and low socio economic status (67.4% and 61.3) patients. Both groups had similar percentage of survivors with more than eight years of scholarship (67%). Median age of survivor from G1 was 39AE10 years and from G2, 32AE9.6 years.
Most of G1 survivors (67.4%) were 25.9 AE10.8 years old at the time of transplant versus 19.5AE10 years old for G2. Malignant diseases were predominant at G1 (60.7%) when compared to G2 (29.8%). At the time of the study, 73% of survivors from G1 and 82% from G2 had 10 to 15 years after HSCT. Pre and post HSCT Karnofsky scores were similar for both groups: G1 (89.9% e 98.9%), G2 (83.9% e 99.2%). Survivors from both groups reported satisfaction with QoL, health, and sexuality. 65.2% from G1 and 75.4% from G2 reported absence of fatigue. These results show that level of satisfaction of long term survivors with their QoL, health, sexuality and fatigue were favorable in spite of having been diagnosed with acute or chronic graft-versus-host-disease. Transplantation provides an opportunity for changes in subjectivity and in facing life's adversities. It is therefore crucial that the QOL assessment can be part of the clinical protocol, once it provides information about risk factor which allow for the best choice of interventions. 
